Results showed that cancer tissue from patients with Carvacrol treatment expressed significantly lower SLC6A3 at both mRNA and protein levels compared with cancer tissue from patients without Carvacrol treatment (Figures 6(a)–6(c)). This evidence concerns the gene SLC6A3 and cancer.